See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
The Oscars
Volodymyr Zelenskyy
Ukraine War
Artificial Intelligence
Social Media
Donald Trump
European Union
US Politics
Rugby
Climate Change
European Politics
Cricket
Published • loading... • Updated

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Summary by PR Newswire
/PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological...

3 Articles

All
Left
Center
1
Right
PR NewswirePR Newswire

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

/PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological...

·United States
Read Full Article
dermatologytimes.comdermatologytimes.com

Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy

Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.

Read Full Article
pipelinereviewpipelinereview

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases - Pipelinereview

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H 2025 BOSTON, MA, USA I February 28, 2025 I Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today a…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Friday, February 28, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal